Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on EGFR TKI treatment. Here, we review the mechanisms of acquired EGFR TKI resistance, the methods for monitoring its appearance, as well as current and future efforts to define treatment strategies to overcome resistance.

中文翻译：

---

克服 EGFR 突变肺癌的治疗耐药性

酪氨酸激酶抑制剂 (TKI) 极大地改变了携带表皮生长因子受体 (EGFR) 激活突变的非小细胞肺癌患者的临床前景。尽管疾病控制时间延长且肿瘤反应率高，但所有患者最终都会在 EGFR TKI 治疗中取得进展。在这里，我们回顾了获得性 EGFR TKI 耐药的机制、监测其出现的方法，以及当前和未来为确定克服耐药的治疗策略所做的努力。